[Federal Register Volume 68, Number 246 (Tuesday, December 23, 2003)]
[Notices]
[Pages 74242-74243]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-31652]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

[[Page 74243]]


ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: (301) 496-7057; fax: (301) 402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Methods and Compositions of Defensin-Antigen Fusion Proteins and 
Chemokine-Antigen Fusion Proteins as Vaccines for Tumors and Viral 
Infection

    Arya Biragyn (NCI).
    PCT Application No. PCT/US01/43830 filed 19 Nov 2001 (DHHS 
Reference No. E-024-2002/0-PCT-02).
    Licensing Contact: Catherine Joyce; (301) 435-5031; 
[email protected].
    This invention relates to the development of a vaccine for 
increasing the immunogenicity of a tumor antigen, thus useful for the 
treatment of cancer, as well as a vaccine for increasing the 
immunogenicity of a viral antigen, thus allowing treatment of viral 
infection. In particular, the present invention provides a fusion 
protein comprising a defensin or chemokine fused to either a tumor 
antigen or viral antigen which is administered as either a protein or 
nucleic acid vaccine to elicit an immune response effective in treating 
cancer or effective in treating or preventing viral infection. In 
particular, the C-C chemokine macrophage inflammatory protein (MIP-
3[alpha]) was shown to be particularly effective in increasing the 
immunogenicity of a tumor antigen. Aspects of this work have been 
published as a PCT patent application with publication number WO 03/
025002.
    This technology is available for licensing on an exclusive or a 
non-exclusive basis.

    Dated: December 16, 2003.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 03-31652 Filed 12-22-03; 8:45 am]
BILLING CODE 4140-01-P